Home > Insider Trading > Filing (0001104659-21-028948)

Filing Details

Accession Number:: 0001104659-21-028948
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2021-02-26 13:21:58
Reporting Period:: 2021-02-24

Accepted Time:: 2021-02-26 13:21:58
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1772028	Scopus Biopharma Inc.	SCPS	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1449211	Scott Ira Greenspan	C/O Scopus Biopharma Inc. 420 Lexington Avenue, Suite 300 New York NY 10170	Executive Committee Chairman	Yes	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock, Par Value $0.001	Acquisiton	2021-02-24	115	$9.48	80,790	No	4	P	Direct
Common Stock, Par Value $0.001	Acquisiton	2021-02-24	300	$9.45	6,950	No	4	P	Indirect	HCFP
Common Stock, Par Value $0.001	Acquisiton	2021-02-25	800	$9.01	7,750	No	4	P	Indirect	HCFP

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Direct
No	4	P	Indirect	HCFP
No	4	P	Indirect	HCFP

Footnotes

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.44 to $9.69 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.44 to $9.46 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4.
Mr. Greenspan is deemed to have shared voting and dispositive power over HCFP-held securities. Mr. Greenspan disclaims beneficial ownership of shares by this entity, except to the extent of his proportionate pecuniary interest therein.
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.00 to $9.02 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (4) to this Form 4.